A framework for global surveillance of antibiotic resistance.

The foreseen decline in antibiotic effectiveness explains the needs for data to inform the global public health agenda about the magnitude and evolution of antibiotic resistance as a serious threat to human health and development. Opportunistic bacterial pathogens are the cause of the majority of community and hospital-acquired infections worldwide. We provide an inventory of pre-existing regional surveillance programs in the six WHO regions which should form the underpinning for the consolidation of a global network infrastructure and we outline the structural components such as an international network of reference laboratories that need to be put in place to address the void of these crucial data. In addition we suggest to make use of existing Health and Demographic Surveillance Sites (HDSS) to obtain crucial information from communities in resource limited settings at household level in low- and middle-income countries in Asia and Africa. For optimising the use of surveillance data for public health action i.e. priority setting for new drug development, comparative quantification of antibiotic effectiveness at local, national, regional and global level and identification of the action gaps can be helpful.

[1]  Ramanan Laxminarayan,et al.  Antimicrobial resistance in developing countries. Part I: recent trends and current status. , 2005, The Lancet. Infectious diseases.

[2]  S. Chihara,et al.  First case of New Delhi metallo-beta-lactamase 1-producing Escherichia coli infection in Japan. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  B. Spratt,et al.  Geographic Distribution of Staphylococcus aureus Causing Invasive Infections in Europe: A Molecular-Epidemiological Analysis , 2010, PLoS medicine.

[4]  Z. Bhutta,et al.  Hospital-acquired neonatal infections in developing countries , 2005, The Lancet.

[5]  K. Manji,et al.  High Rate of Fatal Cases of Pediatric Septicemia Caused by Gram-Negative Bacteria with Extended-Spectrum Beta-Lactamases in Dar es Salaam, Tanzania , 2005, Journal of Clinical Microbiology.

[6]  Markus Herrmann Monopoly pricing of an antibiotic subject to bacterial resistance. , 2010, Journal of health economics.

[7]  D. Monnet,et al.  Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. , 2010, The Journal of antimicrobial chemotherapy.

[8]  I. Okeke,et al.  Antimicrobial resistance in developing countries , 1998, BMJ.

[9]  Shou-Dong Lee,et al.  First identification of a patient colonized with Klebsiella pneumoniae carrying blaNDM-1 in Taiwan. , 2010, Journal of the Chinese Medical Association : JCMA.

[10]  H. Goossens,et al.  The more antibacterial trade names, the more consumption of antibacterials: a European study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Stephan Harbarth,et al.  Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes , 2004, Emerging infectious diseases.

[12]  A D LANGMUIR,et al.  The surveillance of communicable diseases of national importance. , 1963, The New England journal of medicine.

[13]  H. Goossens,et al.  Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  H. Goossens,et al.  Antimicrobial Drug Use and Resistance in Europe , 2008, Emerging infectious diseases.

[15]  F. Tenover,et al.  Ability of Laboratories To Detect Emerging Antimicrobial Resistance: Proficiency Testing and Quality Control Results from the World Health Organization's External Quality Assurance System for Antimicrobial Susceptibility Testing , 2001, Journal of Clinical Microbiology.

[16]  References , 1971 .

[17]  M. Mulvey,et al.  New Delhi Metallo-β-Lactamase in Klebsiella pneumoniae and Escherichia coli, Canada , 2011, Emerging infectious diseases.

[18]  P. Nordmann,et al.  Spread of OXA-48-Encoding Plasmid in Turkey and Beyond , 2010, Antimicrobial Agents and Chemotherapy.

[19]  A. Seck,et al.  Class D OXA-48 Carbapenemase in Multidrug-Resistant Enterobacteria, Senegal , 2011, Emerging infectious diseases.

[20]  Stanley M. Lemon,et al.  WHO Global Strategy for Containment of Antimicrobial Resistance: Executive Summary , 2003 .

[21]  D. Monnet,et al.  Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. , 2000, International journal of antimicrobial agents.

[22]  J. Giesecke,et al.  New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  P. Huovinen,et al.  Drug Resistance Updates , 2000, BMJ : British Medical Journal.

[24]  U. Buchholz,et al.  Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: an external quality assurance exercise of the European Antimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS) , 2002, The Journal of antimicrobial chemotherapy.

[25]  Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. , 2010, MMWR. Morbidity and mortality weekly report.

[26]  J. Högel,et al.  Consumption of Imipenem Correlates with β-Lactam Resistance in Pseudomonas aeruginosa , 2002, Antimicrobial Agents and Chemotherapy.

[27]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.